Close Menu

NEW YORK – A little more than a month into its new life as a publicly traded company, sequencing firm Personalis updated investors this week on how customers have been receiving its recently launched comprehensive tumor and immune profiling assay ImmunoID NeXT, as well as how its efforts to develop an exome-wide liquid biopsy product are proceeding.

Launched through an early-access program that began in January, NeXT combines exome-wide analysis of DNA and RNA with interrogation of the tumor microenvironment in a single FFPE sample.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.